Evidence level: B
辨体论治的”同病异治”,能否被写成一条可检验的数学规则:体质遗传基线(PRS)如何修饰干预获益——答案藏在”乘法无交互、加法有交互”这一现代遗传流行病学的分叉里。
正文
中医讲”辨体论治”:同样一场生活方式干预,痰湿质和阳虚质的人,获益可能不同。现代科学给这个直觉配了一把尺子——多基因风险评分(PRS)。上一篇文章(#364)问了第一个问题:遗传负荷高的人,干预应答是否衰减?本篇问的是更细的第二个问题:体质 PRS 基线本身,是否作为”效应修饰因子”改变干预获益的方向与量级?
先说结论:在遗传流行病学里,这个问题有一个清晰且反复出现的答案分叉——相对风险尺度上几乎无交互,绝对风险尺度上高遗传负荷者获益显著更大。
证据一:相对尺度,干预疗效不随遗传负荷改变。 DPP 研究(Diabetes Prevention Program)用 34 个已确认的 2 型糖尿病位点构建遗传风险评分(GRS),在 2843 名高危参与者中检验 GRS×治疗的交互:GRS 与治疗之间无显著交互(交互 P 不显著),但生活方式干预在最顶 GRS 四分位组依然高度有效(P<0.0001)——遗传风险最高的四分之一人群,恰恰是干预最见效的人群之一(PMID 21378175)。Khera 团队在三个前瞻队列(共 55,685 人)中检验冠脉疾病的遗传风险×生活方式交互,三个队列交互 P 分别 0.38、0.31、0.24,全部不显著;但高遗传风险组中,良好生活方式带来 46% 的相对风险降幅(HR 0.54),十年标准化发病率从 10.7% 降到 5.1%(PMID 27959714)。乘法模型告诉我们的只有一句:干预的相对疗效,对所有遗传基线一视同仁。
证据二:绝对尺度,高遗传负荷者获益最大。 用增强型 PRS(AnnoPred)在 UK Biobank 27.6 万白人中重做检验,结论翻转:生活方式依从带来的绝对风险降幅随 PRS 单调增大——2 型糖尿病 top 1% PRS 组绝对降幅 12.4%,最底层十分位仅 2.8%,比值超过 4.4 倍(PMID 33433237)。中国人群证据更直接:中国慢性病前瞻性研究(CKB,96,400 人)显示,从不良生活方式转为良好生活方式,高遗传风险组的早发冠脉疾病发病率降幅是低风险组的 14.7 倍(PMID 38987358)。”遗传底子差的人更需要改命”——这句话在加法模型下是真命题。
证据三:效应修饰≠风险告知。 把 PRS 告诉患者本身,并不能自动换来行为改变:系统综述汇总 12 项预防性 RCT,PRS 披露仅带来 LDL-C 平均下降 6.39 mg/dL,血压、体重无显著变化,焦虑反而小幅上升(PMID 35488921)。所以”高 PRS 者获益更大”的效应修饰,必须发生在干预真的被执行之后——这正好把检验对象逼回中医场景:干预处方化、个体化执行,正是辨体论治的看家本领。
回到体质。 体质的遗传学证据仍在累积(痰湿质有可复制的代谢位点,FTO 位点与少阴型反向关联已在多队列复制)。但一个必须正视的冷水:最新的 meta-流行病学研究纳入 137 个系统综述、2064 个 RCT,检验”辨证论治是否改善中药疗效估计”——二元结局 ROR 0.93(P=0.04),连续结局 dSMD 无显著差异(P=0.26),即辨证本身在 RCT 层面未显示出对疗效的显著提升(PMID 41671109)。这不是否定辨体论治,而是说:要证明”阳虚/痰湿等体质基线×PRS 高/低亚组→干预获益差异”这一三阶效应修饰真实存在,必须有头对头的交互检验设计,而不能停在经验叙事上。
可检验的骨架:九种体质分型 × PRS 四分位分层 × 随机化生活方式干预;主终点为干预前后体质评分变化与代谢双终点;统计核心是 PRS×干预交互项(相对尺度)与各 PRS 层内的绝对获益差(绝对尺度)——两者都要报告,因为分叉答案本身才是完整答案;再按体质类型做亚组效应修饰检验(体质×PRS×干预三阶交互)。若某体质(如痰湿)的绝对获益-遗传负荷斜率显著异于其他体质,辨体论治的个体化价值就拿到了第一份量化证据;若斜率同构,”辨体”与”辨 PRS”就是冗余信息——这也是科学该给传统的诚实回答。
证据与局限
已验证: PRS×生活方式干预的相对尺度交互在多个大队列中不显著(DPP PMID 21378175;Khera 三队列 PMID 27959714);绝对尺度上高 PRS 组获益显著更大(UK Biobank PMID 33433237 比值>4.4;中国 CKB PMID 38987358 达 14.7 倍);PRS 告知本身促进行为改变的证据薄弱(系统综述 PMID 35488921)。
部分验证: 体质有可复制的遗传位点(痰湿代谢位点、FTO-少阴反向关联),但万人级体质 GWAS 尚未完成(呼应 #362 的 IV 强度审计);辨证论治在 meta-流行病学层面未显示疗效增益(PMID 41671109),提示体质作为效应修饰因子的实证缺口。
待验证: ①”体质×PRS×干预”三阶效应修饰的显著性检验(痰湿/阳虚等体质在 PRS 高/低亚组的干预获益斜率差异);②绝对获益-遗传负荷斜率是否存在体质特异的形状差异(线性 vs 平台);③干预类型×体质×PRS 的交叉效应(饮食、运动、中药、针灸是否各有最优遗传适配人群)。
相关阅读
- 高/低 PRS 分层的生活方式干预 RCT:遗传负荷高者应答是否衰减
- 中医体质 GWAS 工具变量强度审计:体质位点能否扛起孟德尔随机化
- 体质-菌群干预剂量-反应:倒 U 型曲线的体质特异性
- 研究池子:生物频率密码
证据等级: B(效应修饰方法学与 PRS×生活方式交互有 PubMed 直接支撑;”中医体质作为三阶效应修饰因子”属可检验假说)
参考文献: PMID 21378175, PMID 27959714, PMID 33433237, PMID 38987358, PMID 35488921, PMID 41671109, PMID 30515989, PMID 26525880
免责说明:本文属传统知识与科学文献的整理、对照与研究设计讨论,仅供理解与参考,不构成医疗建议,不能替代专业诊断与治疗。文中涉及的效应量、频率区间与暴露结论多为研究报告层面的推断,个体情况差异很大;如有身体不适或健康疑虑,请就医并由专业医师判断。
Does a higher genetic baseline for constitution yield greater or smaller intervention benefits? — Testing the PRS effect modification
Evidence level: B
Can the “different treatment for the same disease based on constitution” (bian ti lun zhi) of differentiation-based therapy be formulated as a testable mathematical rule: How does the physiological polygenic risk score (PRS) baseline modify intervention benefits? The answer lies within the fork of modern genetic epidemiology between “multiplicative no-interaction” and “additive interaction.”
Main Text
Traditional Chinese medicine (TCM) posits bian ti lun zhi (differentiation-based therapy): for the same lifestyle intervention, individuals with different constitutions—such as phlegm-dampness constitution (tan shi) or yang-deficiency constitution (yang xu)—may derive different benefits. Modern science has provided a measuring stick for this intuition: the polygenic risk score (PRS). The previous article (#364) addressed the first question: Does high genetic burden attenuate intervention response? This article addresses the more nuanced second question: Does the PRS baseline itself act as an “effect modifier” altering both the direction and magnitude of intervention benefits?
Conclusion: In genetic epidemiology, this question has a clear and recurring bifurcation in the answer: No significant interaction on a relative risk scale, but significantly greater benefits for high genetic burden on an absolute risk scale.
Evidence 1: Relative Scale, Intervention Efficacy Does Not Vary with Genetic Burden. The Diabetes Prevention Program (DPP) study constructed a genetic risk score (GRS) using 34 confirmed type 2 diabetes loci and tested the GRS × treatment interaction in 2,843 high-risk participants. There was no significant interaction between GRS and treatment (interaction P not significant), yet lifestyle intervention remained highly effective in the top GRS quartile (P<0.0001)—the quarter with the highest genetic risk was actually one of the most responsive groups to intervention (PMID 21378175). Khera’s team tested the genetic risk × lifestyle interaction across three prospective cohorts (totaling 55,685 individuals); interaction P-values were 0.38, 0.31, and 0.24 across the three cohorts respectively, all non-significant. However, in the high genetic risk group, good lifestyle habits yielded a 46% relative risk reduction (HR 0.54), lowering the ten-year standardized incidence rate from 10.7% to 5.1% (PMID 27959714). The multiplicative model tells us only one thing: relative intervention efficacy is treated equally across all genetic baselines.
Evidence 2: Absolute Scale, High Genetic Burden Yields Greatest Benefit. Re-evaluating with an enhanced PRS (AnnoPred) in 276,000 White individuals from the UK Biobank flipped the conclusion: the absolute risk reduction from lifestyle adherence increased monotonically with PRS. The absolute reduction in the top 1% PRS group for type 2 diabetes was 12.4%, compared to only 2.8% in the bottom decile—a ratio exceeding 4.4 times (PMID 33433237). Evidence from the Chinese population is even more direct: The China Kadoorie Biobank (CKB; 96,400 individuals) showed that shifting from poor to good lifestyle habits resulted in a 14.7-fold greater incidence rate reduction for early-onset coronary disease in the high genetic risk group compared to the low-risk group (PMID 38987358). “Those with a weaker genetic foundation need to change their fate more”—this proposition holds true under an additive model.
Evidence 3: Effect Modification ≠ Risk Disclosure. Simply disclosing PRS to patients does not automatically induce behavioral change: a systematic review of 12 preventive RCTs found that PRS disclosure resulted in an average LDL-C decrease of only 6.39 mg/dL, with no significant changes in blood pressure or weight, and a slight increase in anxiety (PMID 35488921). Therefore, the effect modification where “high PRS individuals benefit more” must occur after the intervention is actually executed—which precisely forces the testing back to the TCM scenario: the prescription and individualized execution of interventions are indeed the core competencies of bian ti lun zhi.
Returning to Constitution. Evidence regarding the genetics of constitution is still accumulating (metabolism-related loci for phlegm-dampness constitution have been replicated; the FTO locus shows reverse association with the Shaoyin type across multiple cohorts). However, a cold reality that must be acknowledged: the latest meta-epidemiological study included 137 systematic reviews and 2,064 RCTs testing whether “differentiation-based therapy improves estimates of herbal medicine efficacy.” For binary outcomes, the odds ratio (ROR) was 0.93 (P=0.04); for continuous outcomes, the standardized mean difference (dSMD) showed no significant difference (P=0.26). In other words, differentiation itself did not show a significant improvement in efficacy at the RCT level (PMID 41671109). This is not a denial of bian ti lun zhi, but rather indicates that to prove the three-stage effect modification where “constitution baseline (yang-deficiency/phlegm-dampness etc.) × PRS high/low subgroup → intervention benefit differences” genuinely exists, there must be head-to-head interaction testing designs, rather than stopping at empirical narratives.
Testable Framework: Nine constitution phenotypes × PRS quartile stratification × randomized lifestyle intervention; primary endpoints are changes in constitution scores and metabolic dual endpoints before and after intervention; the statistical core involves the PRS × intervention interaction term (relative scale) and absolute benefit differences within each PRS stratum (absolute scale)—both must be reported because the bifurcated answer itself constitutes the complete truth; further subgroup effect modification tests should be conducted by constitution type (constitution × PRS × intervention three-way interaction). If the absolute benefit-genetic burden slope significantly differs for a specific constitution (e.g., phlegm-dampness) compared to others, the individualized value of differentiation-based therapy receives its first quantitative evidence; if the slopes are isomorphic, “differentiation” and “PRS differentiation” constitute redundant information—this is also the honest answer science should give to tradition.
Evidence and Limitations
Verified: No significant interaction on the relative scale across multiple large cohorts (DPP PMID 21378175; Khera three cohorts PMID 27959714); significantly greater benefits for high PRS groups on the absolute scale (UK Biobank PMID 33433237 ratio >4.4; Chinese CKB PMID 38987358 reached 14.7-fold); weak evidence that PRS disclosure alone drives behavioral change (systematic review PMID 35488921).
Partially Verified: Constitutions have replicable genetic loci (phlegm-dampness metabolism loci, FTO-Shaoyin reverse association), but population-level constitution GWAS is not yet complete (echoing the IV strength audit in #362); differentiation-based therapy did not show efficacy gains at the meta-epidemiological level (PMID 41671109), suggesting an empirical gap regarding constitution as an effect modifier.
To Be Verified: ① Significance testing of the three-stage effect modification (“constitution × PRS × intervention”; difference in intervention benefit slopes for phlegm-dampness/yang-deficiency etc. within high/low PRS subgroups); ② Whether the shape of the absolute benefit-genetic burden slope exhibits constitution-specific differences (linear vs. plateau); ③ Cross-effects of intervention type × constitution × PRS (whether diet, exercise, herbal medicine, or acupuncture each have optimal genetic-matched populations).
Related Reading
- Lifestyle Intervention RCTs Stratified by High/Low PRS: Does High Genetic Burden Attenuate Response
- TCM Constitution GWAS Instrument Strength Audit: Can Constitution Loci Support Mendelian Randomization
- Constitution-Microbiome Intervention Dose-Response: Constitution-Specific Inverted U-Curve
- Research Pool: Biomolecular Frequency Code
Evidence Level: B (Methodology for effect modification and PRS × lifestyle interaction has direct PubMed support; “TCM constitution as a three-stage effect modifier” is a testable hypothesis)
References: PMID 21378175, PMID 27959714, PMID 33433237, PMID 38987358, PMID 35488921, PMID 41671109, PMID 30515989, PMID 26525880
Disclaimer: This article compiles traditional knowledge and scientific literature for comparison and research-design discussion only. It is not medical advice and cannot replace professional diagnosis or treatment. Effect sizes, frequency ranges and exposure conclusions cited here are largely inferences at the research-report level, and individual circumstances vary widely. If you have any discomfort or health concerns, please consult a physician.
Leave a Reply